Nuveen
CHRS icon

Nuveen’s Coherus Oncology CHRS Stock Holding History

Nuveen’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Buy
250,749
+40,370
+19% +$65.9K ﹤0.01% 3446
2026
Q1 		$356K Hold
210,379
– – ﹤0.01% 2966
2025
Q4 		$299K Buy
210,379
+76,629
+57% +$112K ﹤0.01% 3046
2025
Q3 		$219K Buy
133,750
+38,694
+41% +$43K ﹤0.01% 3136
2025
Q2 		$69.5K Hold
95,056
– – ﹤0.01% 3262
2025
Q1 		$76.7K Hold
95,056
– – ﹤0.01% 3238
2024
Q4 		$131K Hold
95,056
– – ﹤0.01% 3269
2024
Q3 		$98.9K Hold
95,056
– – ﹤0.01% 3310
2024
Q2 		$164K Hold
95,056
– – ﹤0.01% 3252
2024
Q1 		$227K Sell
95,056
-666,263
-88% -$1.64M ﹤0.01% 3159
2023
Q4 		$2.54M Sell
761,319
-219,406
-22% -$588K ﹤0.01% 2302
2023
Q3 		$3.67M Buy
980,725
+700,899
+250% +$3.24M ﹤0.01% 2020
2023
Q2 		$1.19M Buy
279,826
+104,167
+59% +$615K ﹤0.01% 2584
2023
Q1 		$1.2M Sell
175,659
-286,867
-62% -$2.23M ﹤0.01% 2543
2022
Q4 		$3.66M Sell
462,526
-266,911
-37% -$2.05M ﹤0.01% 2090
2022
Q3 		$7.01M Sell
729,437
-158,148
-18% -$1.6M ﹤0.01% 1697
2022
Q2 		$6.43M Sell
887,585
-142,021
-14% -$1.23M ﹤0.01% 1783
2022
Q1 		$12.5M Buy
1,029,606
+323,408
+46% +$4.11M ﹤0.01% 1501
2021
Q4 		$11.3M Sell
706,198
-17,745
-2% -$310K ﹤0.01% 1617
2021
Q3 		$11.6M Sell
723,943
-36,788
-5% -$539K ﹤0.01% 1674
2021
Q2 		$10.5M Buy
760,731
+83,940
+12% +$1.19M ﹤0.01% 1835
2021
Q1 		$9.89M Buy
676,791
+15,985
+2% +$271K ﹤0.01% 1808
2020
Q4 		$11.5M Sell
660,806
-479,065
-42% -$8.53M ﹤0.01% 1619
2020
Q3 		$20.9M Sell
1,139,871
-3,004
-0.3% -$55.9K 0.01% 1032
2020
Q2 		$20.4M Sell
1,142,875
-100,961
-8% -$1.71M 0.01% 1036
2020
Q1 		$20.2M Sell
1,243,836
-697,864
-36% -$12.9M 0.01% 897
2019
Q4 		$35M Buy
1,941,700
+111,785
+6% +$2.06M 0.01% 862
2019
Q3 		$37.1M Buy
1,829,915
+667,224
+57% +$13.3M 0.02% 811
2019
Q2 		$25.7M Buy
+1,162,691
New +$20.2M 0.01% 1024

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Nuveen's CHRS Position: Q2 2026 in Review

Nuveen increased its Coherus Oncology (CHRS) stake by 19% in Q2 2026, buying an estimated $65.9K and bringing the position to 250,749 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.

Nuveen first reported a position in CHRS in Q2 2019 and has held it in 29 quarters since. The position peaked at $37.1M in Q3 2019. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Nuveen held 250,749 shares of Coherus Oncology worth $351K as of Q2 2026.
  • Nuveen bought 40,370 Coherus Oncology shares in Q2 2026, an estimated $65.9K.
  • Coherus Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3446 holding.
  • Nuveen first reported a position in Coherus Oncology in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Coherus Oncology position peaked at $37.1M in Q3 2019.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.